We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

A Study of the Human Anti-TNF Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: March 6, 2003
Last Update Posted: August 15, 2006
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Purpose of the study is to test whether adalimumab can induce clinical remission in subjects with active Crohn's disease when compared to placebo (an inactive substance)

Condition Intervention Phase
Crohn's Disease Drug: Adalimumab (D2E7) Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Phase II Study of the Human Anti-TNF Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease

Resource links provided by NLM:

Further study details as provided by Abbott:

Primary Outcome Measures:
  • comparison of the induction of clinical remission
  • (achievement of a CDAI <150) of adalimumab 40 mg and 80 mg vs. placebo at Week 4.

Estimated Enrollment: 300
Study Start Date: April 2002

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Diagnosis of Crohn's disease
  • CDAI score at baseline of between 220 and 450
  • Normal laboratory parameters
  • Willing and able to give informed consent


  • Diagnosis of ulcerative colitis
  • Women cannot be pregnant or breastfeeding
  • No previous use of infliximab or other anti-TNF antagonists
  • No previous history of tuberculosis or listeria infection
  • No previous history of cancer other than successfully treated skin cancer
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00055523

  Hide Study Locations
United States, California
Gastroenterology Associates of the East Bay
Berkeley, California, United States, 94705
Long Beach Gastroenterology Assoc.
Long Beach, California, United States, 90806
Sharp Rees-Stealy Medical Group
San Diego, California, United States, 92123
United States, Connecticut
Gastroenterology Assoc. of Fairfield Co.
Bridgeport, Connecticut, United States, 06606
United States, Florida
Cleveland Clinic Florida
Weston, Florida, United States, 33331
Shafran Gastroenterology Center
Winter Park, Florida, United States, 32789
United States, Georgia
Atlanta Gastroenterology Assoc.
Atlanta, Georgia, United States, 30342
Southeastern Digestive & Liver Disease
Savannah, Georgia, United States, 31404
United States, Illinois
Northwest Gastroenterologists, S.C.
Arlington Heights, Illinois, United States, 600005
University of Chicago
Chicago, Illinois, United States, 60637
United States, Louisiana
Drug Research Services, Inc.
Metairie, Louisiana, United States, 70001
LSU School of Medicine
New Orleans, Louisiana, United States, 70115
United States, Maryland
Digestive Disorders Associates
Annapolis, Maryland, United States, 21401
United States, Massachusetts
Brigham and Women's Hospital
Boston, Massachusetts, United States, 002115
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Clinical Pharmacology Study Group
Worcester, Massachusetts, United States, 01610
United States, Minnesota
Mayo Clinic and Mayo Foundation
Rochester, Minnesota, United States, 55905
United States, Missouri
Gastroenterology and Hepatology
Kansas City, Missouri, United States, 64131
Glenn Gordon, MD
Mexico, Missouri, United States, 65265
United States, Montana
Deaconess Billings Clinic Research Division
Billings, Montana, United States, 59101
United States, Nebraska
Gastroenterology Specialties, P.C.
Lincoln, Nebraska, United States, 68503
United States, New York
Long Island Clinical Research Associates
Great Neck, New York, United States, 11021
NY Center for Clinical Research
Lake Success, New York, United States, 11042
New York Presbyterian Hospital
New York, New York, United States, 10021
Daniel Present
New York, New York, United States, 10029
Rochester Institute for Digestive Diseases
Rochester, New York, United States, 14607
United States, North Carolina
UNC School of Medicine
Chapel Hill, North Carolina, United States, 27599
Charlotte Gastroenterology and Hepatology
Charlotte, North Carolina, United States, 28207
Carolina Research Associates
Charlotte, North Carolina, United States, 28262
Wake Research Associates
Raleigh, North Carolina, United States, 27612
Digestive Health Specialists
Winston-Salem, North Carolina, United States, 27103
United States, Ohio
Consultants for Clinical Research
Cincinnati, Ohio, United States, 45219
United States, Oklahoma
Oklahoma Foundation for Digestive Disease
Oklahoma City, Oklahoma, United States, 73104
Research Solutions
Tulsa, Oklahoma, United States, 74104
United States, Pennsylvania
Altoona Center for Clinical Research
Duncansville, Pennsylvania, United States, 16635
Peter Molloy, MD
Pittsburgh, Pennsylvania, United States, 15224
United States, Tennessee
Diseases of the Digestive System
Chattanooga, Tennessee, United States, 37421
Nashville Medical Research Institute
Nashville, Tennessee, United States, 37205
United States, Virginia
Charlottesville Medical Research
Charlottesville, Virginia, United States, 22902
United States, Washington
Northwest Gastroenterology
Bellevue, Washington, United States, 98004
Inland Empire Gastroenterology
Spokane, Washington, United States, 99204
Tacoma Digestive Disease Center
Tacoma, Washington, United States, 98405
United States, Wisconsin
Wisconsin Center for Advanced Research
Milwaukee, Wisconsin, United States, 53702
Sponsors and Collaborators
Principal Investigator: Stephen B Hanauer, MD University of Chicago Department of Medicine
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00055523     History of Changes
Other Study ID Numbers: M02-403
First Submitted: March 4, 2003
First Posted: March 6, 2003
Last Update Posted: August 15, 2006
Last Verified: August 2006

Additional relevant MeSH terms:
Crohn Disease
Inflammatory Bowel Diseases
Gastrointestinal Diseases
Digestive System Diseases
Intestinal Diseases
Immunologic Factors
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents